english.prescrire.org > Spotlight > Archives : 2026 > GLP-1 and dual GLP-1/GIP agonists: ischaemic optic neuropathy

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

GLP-1 and dual GLP-1/GIP agonists: ischaemic optic neuropathy

 Adverse Effects  In 2025, we reported that a US epidemiological study had found that injections of the GLP-1 agonist semaglutide were associated with an increased risk of non-arteritic anterior ischaemic optic neuropathy. Is this an adverse effect of all GLP-1 agonists and of tirzepatide, which is also a GIP agonist?
Full article available for download by subscribers

 ©Prescrire 1 May 2026

Source: "GLP-1 and dual GLP-1/GIP agonists: ischaemic optic neuropathy" Prescrire Int 2026; 35 (281): 129-130. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Semaglutide:
optic neuropathy"
Prescrire Int 2025;
34 (269): 107.
Subscribers only